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Summary
Variegate porphyria (VP) is a low-penetrance, autosomal
dominant disorder characterized clinically by skin le-
sions and acute neurovisceral attacks that occur sepa-
rately or together. It results from partial deficiency of
protoporphyrinogen oxidase encoded by the PPOX
gene. VP is relatively common in South Africa, where
most patients have inherited the same mutation in the
PPOX gene from a common ancestor, but few families
from elsewhere have been studied. Here we describe the
molecular basis and clinical features of 108 unrelated
patients from France and the United Kingdom. Muta-
tions in the PPOX gene were identified by a combination
of screening (denaturing gradient gel electrophoresis,
heteroduplex analysis, or denaturing high-performance
liquid chromatography) and direct automated sequenc-
ing of amplified genomic DNA. A total of 60 novel and
6 previously reported mutations (25 missense, 24 frame-
shift, 10 splice site, and 7 nonsense) were identified in
104 (96%) of these unrelated patients, together with
3 previously unrecognized single-nucleotide polymor-
phisms. VP is less heterogeneous than other acute por-
phyrias; 5 mutations were present in 28 (26%) of the
families, whereas 47 mutations were restricted to 1 fam-
ily; only 2 mutations were found in both countries. The
pattern of clinical presentation was identical to that re-
ported from South Africa and was not influenced by type
of mutation. Our results define the molecular genetics
of VP in western Europe, demonstrate its allelic heter-
ogeneity outside South Africa, and show that genotype
is not a significant determinant of mode of presentation.
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Introduction
Variegate porphyria (VP [MIM 176200]) is a disorder
of heme biosynthesis and results from partial deficiency
of protoporphyrinogen oxidase (PPOX [E.C.1.3.3.4])
(Brenner and Bloomer 1980; Kirsch et al. 1998). As im-
plied by its name, it presents in different ways—either
with skin fragility and bullae, with acute neurovisceral
crises, or with both together (Kirsch et al. 1998). Symp-
toms are very rare before puberty. The disorder is in-
herited in an autosomal dominant pattern with low clin-
ical penetrance. Approximately three-quarters of those
affected remain asymptomatic but are at risk for devel-
opment of acute neurovisceral crises if they are exposed
to certain drugs, alcohol, or other provocative factors
(Jenkins 1996; Elder et al. 1997; Kirsch et al. 1998).
Detection of asymptomatic affected individuals—so that
they can be advised to avoid provoking agents—is an
important part of the management of families with VP.
Biochemical methods for their detection are technically
complex or insensitive (Long et al. 1993; Da Silva et al.
1995).
The 5-kb PPOX gene on chromosome 1q 22-23 con-
tains 1 noncoding and 12 coding exons (Nishimura et
al. 1995; Roberts et al. 1995; Taketani et al. 1995; Puy
et al. 1996). Mutations in this gene have been shown to
cause VP (Deybach et al. 1996; Lam et al. 1996, 1997;
Meissner et al. 1996; Warnich et al. 1996; de Rooij et
al. 1997; Frank et al. 1997a, 1997b, 1998a, 1998b,
1998c, 1998d; Kauppinen et al. 1997; Corrigall et al.
1998; also see Human Gene Mutation Database) and
the rare related condition, homozygous VP (Meissner et
al. 1996; Frank et al. 1998e; Roberts et al. 1998). VP
is common in South Africa, where an estimated 20,000
descendants of a Dutch couple who married at the Cape
in 1688 have inherited the same mutation (R59W) in
the PPOX gene (Dean 1971; Meissner et al. 1996; War-
nich et al. 1996; Groenewald et al. 1998). Outside South
Africa, the disease is less common but is increasingly
becoming recognized, as confusion with porphyria cu-
tanea tarda or other acute porphyrias is resolved by ap-
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plication of more-precise diagnostic methods (Poh-Fitz-
patrick 1980; Long et al. 1993). Apart from one series
of 57 patients from Finland (Mustajoki 1980), of whom
only 18 had symptoms, only small numbers of cases have
been reported outside South Africa (Armas et al. 1992;
Kirsch et al. 1998). PPOXmutations that cause VP have
recently been identified in a few families (Deybach et al.
1996; Lam et al. 1996, 1997; de Rooij et al. 1997; Frank
et al. 1997a, 1997b, 1998a, 1998b, 1998c, 1998d;
Kauppinen et al. 1997) from Europe and the United
States, but neither the extent of allelic heterogeneity, the
distribution of mutations within the PPOX gene, nor
genotype-phenotype correlations have yet been studied
in a large group of patients. Here we report an inves-
tigation of the PPOX gene in 108 apparently unrelated
patients with VP who are from France and the United
Kingdom.
Patients and Methods
Patients
We studied 108 apparently unrelated patients with VP
who presented sequentially for mutational analysis. Of
these, 103 patients had current or past symptoms of VP;
5 patients had never had symptoms but were referred
because of a family history of either acute or cutaneous
porphyria and were found, by biochemical investigation,
to have VP. In all 108 patients, the diagnosis was es-
tablished by fecal porphyrin measurement, PPOX assay,
or fluorescence-emission spectroscopy of plasma (Long
et al. 1993; Da Silva et al. 1995). The mode of presen-
tation (skin lesions alone, acute attack alone, or both
together) was recorded on all symptomatic patients. Un-
relatedness was determined by family inquiries; none of
the patients were known to be related. Of the 108 pa-
tients, 51 (34 female and 17 male) came from France
and 57 (42 female, 15 male) came from the United King-
dom. Patients resided throughout the United Kingdom
and France; all were white.
Identification of Mutations
DNA was extracted from peripheral blood leukocytes
or Epstein-Barr virus–transformed lymphoblasts. Exons
1–13 of the PPOX gene, along with 45–160 bp of their
flanking regions, were amplified by means of the primers
and conditions listed in table 1 and were screened for
mutations, by either heteroduplex analysis (HDA) (ex-
ons 1–7, 12, and 13) or denaturing gradient gel electro-
phoresis (DGGE) (exons 8–11). Preliminary computer
analyses of genomic PPOX sequence were performed
with the MELT 87 and SQHTX programs, written and
kindly provided by Lerman and Silverstein (1987). They
predicted optimal experimental conditions for DGGE
only in exons 8–11. For these exons, DGGE analyses
were performed according to the method of Myers et al.
(1987). HDA was used as an alternative mutation-
screening method for those exons not analyzable by
DGGE. The gels used for HDA were prepared with a
polyacrylamide-derived commercial matrix, MDE
(mutation-detection enhancement; FMC Bioproducts).
Regions showing abnormal patterns were sequenced to
identify mutations and polymorphisms.
When no abnormality was detected by DGGE or
HDA, exons 4, 7, 8, and 10–13, along with 55–256 bp
of their flanking regions, were screened by denaturing
high-performance liquid chromatography (RP-HPLC),
as described elsewhere (O’Donovan et al. 1998), and
520 bp 5′ to exon 1, exons 1–3, 5, 6, and 9 and their
flanking regions were sequenced. For those patients in
whom no abnormality was found by HPLC, exons 4, 7,
8, and 10–13 and their flanking regions were sequenced.
For DNA sequencing, the PPOX gene was amplified
in four fragments—exons 1–4 with 520 bp 5′ to exon 1
(1,565 bp), exons 3–7 (2,014 bp), exons 7–9 (1,071 bp),
and exons 10–13 (851 bp)—by means of the primers
and conditions listed in table 1. PCR-amplified double-
stranded DNA was purified from agarose gels by means
of a Qiaquick gel-extraction kit (Qiagen) and was cycle
sequenced by means of fluorescent ddNTPs (Ampli-
taqFS, Rhodamine, or BigDye) and an ABI 377 auto-
mated sequencer (PE Biosystems). Sequencing primers
were chosen to include 58–250 bp of flanking regions.
Sequences were analyzed by visual inspection. The pres-
ence of mutations was confirmed either by sequencing
of both DNA strands or by digestion, with the appro-
priate restriction enzyme, of amplified DNA.
RNA Analysis
For investigation of splicing of exon 8, RNA was ob-
tained by extraction from phytohemagglutinin (PHA)-
transformed lymphocytes and was reverse transcribed as
described elsewhere (Roberts et al. 1998). cDNA for
PPOXwas amplified by PCRwith a sense primer in exon
6 (5′-AGGTCCTGCTTTCCCAGTCTCTTC) and an
antisense primer in exon 13 (5′-TATTTTCATGAAT-
GAGAGTTGGGGATC). The product was purified from
a 2% agarose gel by means of a Qiaquick gel-extraction
kit, and both strands were sequenced as described above.
Polymorphisms
The frequency of known and suspected single-nucle-
otide polymorphisms (SNPs) in the PPOX gene were
determined by study of either 105 unrelated subjects (65
French and 40 U.K.) or 78 nonporphyric white families
from the Centre d’Etude du Polymorphisme Humain
(Paris), by means of either direct sequencing, restriction-
enzyme digestion, DGGE, or HDA (table 2). Homozy-
gosity or heterozygosity at intragenic polymorphic sites
Table 1
Sequence of Oligonucleotide Primers and Conditions Used in PCR and DGGE or HDA Analysis of All PPOX Exons
Exon and
Primer 5′-Sequencea
Size
(bp)
Conditions
PCR
DGGEb HDAb
MgCl2
(mM)
Temperature
(C)
1:
PV 617 S CCAAGTCCCGCCAATCCAGAT 360 1.5 61 ) 500 V for 10 h
PV 956 AS ACGGATGGGCTGGTGGAACAG
2:
PV-MDE-2S CTGGACGGGGACCTCGCTGTT 355 1.0 60 ) 500 V for 10 h
PV-MDE-2AS GTAGGGAGGGGTAAGAGGCATATT
3:
PV-MDE-3S CCCTCTGAATATGCCTCTTAC 305 1.0 56 ) 500 V for 10 h
PV-MDE-3AS AACATACTTCCTCCCCTAAAC
4:
PV 1544-S GGGAATAGAGTTTAGGGGAGGA 272 1.5 56 ) 500 V for 10 h
PV 1785-AS GAAGAAAGAAATGGAAGGCATA
5:
PV-MDE-5S TGGAGCTGGGGAGGTATGTC 234 1.0 56 ) 500 V for 10 h
PV-MDE-5AS CTGGTTTAGGAGGGAAGAGG
6:
PV-MDE-6S CCCACCCTCATTCCCTACCA 307 1.0 56 ) 500 V for 10 h
PV-MDE-6AS AGCACCCCTTGTCCCCACTC
7:
PV 2196-S CCTAAAGTGCTGGGATTACA 316 1.5 56 ) 500 V for 10 h
PV 2485-AS TGGATAAAGATGGAAACACTGA
8:
PV 3774-S-Cl (GC)50CAATCTCTTCATCCTGGGTCAG 348 1.5 56 40%–90%, 150 V for 6 h )
PV 4051-AS AGTTCAGGGGCATGGTGTGGT
9:
PV 4051-S-Cl (GC)50ACCACACCATGCCCCTGAAC 370 1.0 59 40%–90%, 150 V for 6 h )
PV 4370-AS GCCAGGCTGGTCTCGAACTC
10:
PV 4538-S-Cl (GC)50ATTACACTCCAGCCTGGGTGA 383 1.5 56 40%–90%, 150 V for 6 h )
PV 4849-AS AAGGAGGGAATATAGCACTGAT
11:
PV 4762-S TCAGAGTGACTGTGAGGAGGAG 433 1.5 56 40%–90%, 150 V for 6 h )
PV 5121-AS-Cl (GC)50AGGATGCAGGGAAAAGTTTATTAT
12 and 13:
PV 5074-S AGACTGGAACATTTGTCACTGT 401 1.5 54 ) 500 V for 10 h
PV 3851-AS AAGCCAAGCCAAGCAATTTT
1–4:
V3169-S GAGGTTATGTACTGGGAGGA 1565c 1.5 64
A6166-AS CACGTAGAGGAACCTGTTCTGGGCAGC
4–7:
A6167-S TTGTGGGATGTCTAGGAGAGGTTG 2014 1.5 64
A6168-AS GTAGCCCATGTCTAAGTAGCTTCTAAG
7–9:
P2052-S AGTGGTCACTTCGTGGAG 1071 1.5 64
V8508-AS CGAACTCCTGACCTTGTTATC
10–13:
T2713-S GAGAGACAGCCTCAGCTAG 851 1.5 61
W7097-AS TATTTTCATGAATGAGAGTTGGGGATC
a The sequence of GC clamp is as follows: (GC)50 = CGCCCGCCGCGCCCCGCGCCCGTCCCGCCGCCCCCGCCCGCCCCCGCCCG.
b Percentages are of denaturant (100% = 7 M urea and 40% [v/v] formamide), and time is for electrophoresis at 60C.
c Includes 520 bases of 5′ UTR.
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Table 2
SNPs in the Human PPOX Gene
Exon/Intron
and Positiona Screening Method
Allele
(Frequency)
Exon 1:
253 Direct sequencing G (1.00)
C (0.0)
247 Direct sequencing A (.46)
C (.54)
246 Direct sequencing G (1.00)
T (.00)
151 Direct sequencing G (.93)
T (.07)
118 Direct sequencing C (.84)
G (.16)
Intron 2:
IVS247 HDA G (.61)
C (.39)
Intron 4:
IVS4327 HinfI digestion G (.94)
A (.06)
Intron 6:
IVS6150 SfcI digestion T (.96)
C (.04)
IVS6237 Direct sequencing A (.73)
C (.27)
Exon 7:
767 (P256R)b HDA C (.95)
G (.05)
Intron 8:
IVS857b DGGE A (.96)
C (.04)
Exon 9:
911 (R304H) DGGE G (.61)
A (.39)
Intron 10:
IVS1022b DGGE G (.97)
C (.03)
a Nucleotides are numbered according to the PPOX
cDNA sequence (see “Numbering System” subsection
in text).
b Previously unrecognized SNPs.
Figure 1 Distribution of mutations in the human PPOX gene.
Missense mutations (•) are shown below the gene diagram, with chain
termination and splice mutations (frameshift [#], nonsense [], and
splice defects []) above it. Unshaded areas of exons denote noncoding
regions.
was determined for all patients with mutations that were
present in four or more families; partial haplotypes were
deduced by comparison of the profiles of polymorphic
variation for individuals who shared a mutation.
Numbering System
Nucleotides are numbered according to the cDNA
sequence derived from the PPOX genomic sequence
(Puy et al. 1996) (HGMP GenBank accession number
X99450), in which the A of the ATG initiation codon
is numbered “1.”
Results
Identification of Mutations
Initially, exons 1–13 and their flanking regions were
amplified from genomic DNA from all 108 unrelated
patients with VP. Amplified fragments were screened by
either HDA or DGGE, and any showing abnormal pat-
terns were sequenced. This approach identified 54 mu-
tations in 82 patients and 3 SNPs in addition to the 10
SNPs reported elsewhere (Puy et al. 1996; Warnich et
al. 1996; Lam et al. 1997; Kotze et al. 1998) (table 2).
A total of 13 mutations were identified in 22 of the other
26 patients, by either direct sequencing (9 mutations) or
HPLC (4 mutations). Sequencing of all exons, their
flanking regions, and 520 bp upstream from exon 1
failed to detect any base change in the four remaining
patients. Each of these four patients was hetero-
zygous for one intragenic SNP (247A/C, 118C/G,
IVS247C/G, or 911A/G).
Overall, analysis of exons 1–13 by HDA or DGGE
identified 54 (77%) of 70 mutations, if it is assumed
that the four patients with undetected mutations all had
different mutations. All 11 SNPs found in the population
that we studied gave abnormal patterns on HDA or
DGGE, facilitating screening of sufficient subjects to es-
tablish allele frequencies (table 2). Direct automated
DNA sequencing detected 66 mutations in 104 (96%)
of our 108 patients, giving this method a sensitivity of
94% (66 of 70 mutations detected) (95% confidence
interval 90%–99%).
Distribution and Type of Mutation
Mutations were distributed throughout the coding
region of the PPOX gene, with no exon having 110 or
!2 (fig. 1 andtable 3); 24 (36%) of the mutations were
small insertions or deletions that introduced a frame-
shift leading to a stop codon; 25 (38%) were mis-
sense, including one codon deletion (841–843delCAC
[H281del]) and three that altered the initiation codon;
9 (14%) changed invariant nucleotides at splice sites;
and 7 (11%) produced stop codons (fig. 1 andtable 3).
In one patient, the only base change identified
was adjacent to the splice-acceptor site of exon 8
(IVS79TrG). Reverse transcription–PCR of cDNA
Table 3
Mutations in the PPOX Gene in VP
Exon/Intron
and Mutation Effect Screen
Restriction-
Enzyme Site Country
No. of
Families
Exon 2:
1ArG M1V HDA NlaIII France 1
1ArC M1L HDA NlaIII France 1
3GrC M1I HDA NlaIII France 1
45GrC L15F HDA EaeI United Kingdom 7
Exon 3:
113GrC R38P ) BslI France 1
119GrA G40E HDA MnlI France 1
157–160delATCT Stop13 HDA United Kingdom 1
199–200insT Stop10 HDA BglI France 1
218TrC L73P ) BsaJI United Kingdom 1
Intron 3:
IVS31GrC Deletion of exon 4 ) MaeIII France 1
Exon 4:
251TrG V84G HDA CviJI United Kingdom 1
254TrC L85P HDA France 2
Exon 5:
363–364insC Stop21 HDA United Kingdom 2
376–377delCT Stop16 HDA MnlI United Kingdom 1
428ArT D143V HDA France 1
454CrTa R152C ) HhaI France 1
460del23 Stop15 HDA United Kingdom 1
461TrC L154P HDA EcoRI France 1
Exon 6:
472GrA V158M HDA France 1
503GrAb R168H HDA NcoI France and United
Kingdom
2
515CrT A172V ) France 1
528–529insT Stop1 HDA France 1
538–539delATc Stop10 HDA MvaI United Kingdom 2
542–556del15 Stop291 HDA France 1
565delC Stop44 HDA United Kingdom 1
565CrT E189X HDA United Kingdom 4
593TrG L198X HDA France 1
Intron 6:
IVS61GrT Deletion of exon 6 HDA France 1
IVS61GrT Deletion of exon 7 HDA PstI France 1
Exon 7:
672GrA W224X HDA and DGGE NlaIV France 2
694GrCd G232R DGGE MnlI France 2
695GrC G232R HDA and DGGE MnlI France 1
745–746insCd Stop31 HDA and DGGE DdeI France 1
745delG Stop23 HDA and DGGE France and United
Kingdom
2
745–746insG Stop31 HDA and DGGE TaqI France 1
803GrA W268X HDA and DGGE MaeI United Kingdom 2
Intron 7:
IVS72TrC Deletion of exon 7 HPLC United Kingdom 1
IVS79TrG 8 bp into cDNA DGGE NlaIII United Kingdom 1
Exon 8:
841–843delCAC H281del HDA and DGGE France 3
845TrA V282D HPLC MaeIII United Kingdom 2
856delA Stop20 HDA and DGGE France 1
868GrC V290L (deletion of exon 8) DGGE MaeIII United Kingdom 1
Exon 9:
884TrC L295P DGGE United Kingdom 6
Intron 9:
IVS91GrC Deletion of exon 10 DGGE EcoRII United Kingdom 1
(continued)
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Table 3 (continued)
Exon/Intron
and Mutation Effect Screen
Restriction-
Enzyme Site Country
No. of
Families
Exon 10:
1004TrG V335G DGGE France 1
1048TrC S350P DGGE HinfI United Kingdom 1
1053–1054insT Stop3 HDA and DGGE United Kingdom 1
1081–1082insG Stop19 HDA and DGGE BglI United Kingdom 2
1082–1083insC Stop18 HDA and DGGE BglI France 6
1083delTe Stop3 HDA and DGGE BglI France 1
1083–1084insG Stop18 HDA and DGGE BglI France 1
1090–1091delAG Stop15 HDA and DGGE AlwNI United Kingdom 1
Intron 10:
IVS101GrT Deletion of exon 11 DGGE DdeI France 1
Exon 11:
1119GrA W373X DGGE ApyI France 1
1147–1148delGT Stop50 HPLC France 1
Exon 12:
1274–1275delGT Stop7 HDA MaeIII United Kingdom 1
1281GrA W427X ) BstI United Kingdom 1
1287delA Stop HDA and DGGE France 2
Intron 12:
IVS121delG Deletion of exon 12 HDA SpeI France 2
IVS122ArG Deletion of exon 13 HDA MspI United Kingdom 1
Exon 13:
1292–1293delAG Stop2 ) HinfI United Kingdom 2
1303CrT Q435X HPLC United Kingdom 5
1331TrC L444P HDA United Kingdom 1
1357GrA G453R ) United Kingdom 1
1358GrT G453V ) United Kingdom 1
1384–1385delAG Stop13 HDA and DGGE France 1
a Previously reported by Frank et al. (1998c).
b Previously reported by Frank et al. (1998b).
c Previously reported by Corrigall et al. (1998).
d Previously reported by Deybach et al. (1996).
e Previously reported by Frank and Christiano (1997).
for PPOX (exons 6–13) from this patient gave a prod-
uct (∼900 bp) of the size (918 bp) predicted for the
normal allele. Sequencing of this product showed a
mixture of similar quantities of two cDNA spe-
cies—one from the normal allele and one with addition
of 8 bp to the 5′ end of exon 8—indicating that this
mutation creates an additional splice-acceptor site
(GTTTTCAG[GCTCTCAG––––––) that is used in
preference to the normal site.
Allelic Heterogeneity
Five mutations were present in four to seven families
(table 3), accounting for a total of 28 (26%) of our 108
families. All other mutations were present in three or
fewer families, with 47 being restricted to a single family
(table 3).
The disease was less heterogeneous in the UnitedKing-
dom than in France. Of the 37 mutations identified in
French families, only 1 (1082insC) was found in more
than three families, being present in six families (12%
of the 47 families) (table 3). In contrast, 4 of the 31
mutations in U.K. patients (i.e., mutations L15F, E189X,
L295P, and Q435X) were found in 22 (39%) of the
families from that country (table 3). Analysis of intra-
genic polymorphisms showed that the L15F and Q435X
mutations were each associated with at least two dif-
ferent haplotypes (mutation L15P—haplotypes [247A,
151G, IVS247G, 911A] and [247A, 151G,
IVS247G, 911G]; and mutation G435X—haplotypes
[151G, 181C, IVS247C, 911G] and [151G,
181C, IVS247G, 911G]), indicating that neither mu-
tation is likely to have been inherited from a single com-
mon ancestor. For the three other mutations, this anal-
ysis did not exclude common ancestry.
Only two infrequent mutations (503GrA [R168H]
and 745delG) were found in both countries (table 3),
and both occur at potentially hypermutable sites: a CpG
dinucleotide on the antisense strand (R168H) and a
polyG tract (745delG) (Cooper and Krawczak 1993).
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Table 5
VP Clinical Features and Type of Mutation
CLINICAL
FEATURE(S)a
NO. OF PATIENTS (%) OF TOTAL
WITH MUTATION TYPE
Missense
( )n = 38
Splice Site
( )n = 11
Nonsense
or Frameshift
( )n = 51
Skin lesions alone 18 (47%) 5 (45%) 35 (69%)
Acute attack alone 12 (32%) 1 (10%) 7 (14%)
Both together 8 (21%) 5 (45%) 9 (17%)
a At presentation, in the index case from 100 unrelated fam-
ilies. Differences between groups are not significant ( 2x =
; ).5.33 P = .07
Table 4
VP Clinical Features
CLINICAL
FEATURE(S)
NO. (%) IN SUBJECTS FROM
Present
Study ( )an = 103
South Africab
( )n = 269
Skin lesions alone 61 (59%) 156 (58%)
Acute attack alone 20 (20%) 51 (19%)
Both together 22 (21%) 62 (23%)
a Figures for France and the United Kingdom were
not significantly different. Clinical information was
available for 103 of the 108 unrelated patients.
b Data are from Eales et al. (1980).
Phenotype-Genotype Relationship
VP presents clinically in three distinct ways: with skin
lesions alone, with an attack of acute porphyria without
skin lesions, or with both together. The numbers of our
patients in each category are shown in table 4. Percent-
ages did not differ significantly between France (59%
cutaneous) and the United Kingdom (58% cutaneous)
and are very close to those reported elsewhere for a large
series from South Africa (Eales et al. 1980; Kirsch et al.
1998).
Table 5 shows the relationship between mode of pre-
sentation and type of mutation. Although truncating
mutations (frameshift, nonsense, or splice site) appear
to be associated with presentation with skin lesions
alone, the difference was not statistically significant
( ; ). Four of the five mutations that were2x = 5.33 P = .07
present in five or more families were associated with
more than one type of clinical presentation; all patients
with the 1082insC mutation presented with skin lesions
alone.
Discussion
Here we have documented the clinical features and
molecular basis of VP in 108 unrelated patients from
western Europe. Mutations were identified in genomic
DNA by a combined screening and sequencing ap-
proach. DGGE, which has been shown to be highly ef-
fective for the detection of mutations in the other acute
porphyrias (Puy et al. 1997; Rosipal et al. 1999), cannot
be applied to the whole of the PPOX gene, and HDA
is known to lack sensitivity (Tchernitchko et al. 1999).
However, all the mutations that we identified could be
detected by direct automated sequencing of exons and
their flanking regions, and this would appear to be the
method of choice for mutational analysis of VP.
Mutations were not identified in four patients. Com-
plete deletions of the PPOX gene were excluded by
showing that each of these patients was heterozygous
for an intragenic SNP. All had an unequivocal diagnosis
of VP, and it is probable that the causative mutations
either lie outside the gene regions that we sequenced or
were partial deletions or insertions not detectable by our
PCR-based methods.
Two patients had both a chain-termination or splice
mutation (IVS61GrT or 1054insT, respectively) and
a missense mutation (767CrG [P256R]) that were
shown, by family studies, to be on the same allele. The
P256R mutation has previously been reported to be one
of two mutant PPOX alleles in a compound heterozy-
gote with homozygous VP (Kauppinen et al. 1997). In-
vestigation of 156 normal alleles showed that this mu-
tation, which affects a residue that is poorly conserved
between species (fig. 2), is a polymorphism present in
∼10% of the French population (table 2). Two previ-
ously unreported intragenic SNPs were also identified
(table 2). Five single-base changes in exon 1 have re-
cently been reported in VP and have been interpreted as
evidence that this UTR of the gene is particularly mu-
tation prone (Kotze et al. 1998). We sequenced exon 1
from 45 patients with VP and were unable to confirm
this finding; two of the SNPs found by Kotze et al. (1998)
in only three normal controls (i.e., mutations 253G/C
and 246G/C) were not present in our cohort (table 2).
We have identified 66 different mutations in the
PPOX gene in VP (table 3), 60 of which are novel,
bringing the total number of mutations reported in this
condition to 79 (Deybach et al. 1996; Lam et al. 1996,
1997;Meissner et al. 1996;Warnich et al. 1996; de Rooij
et al. 1997; Frank et al. 1997a; Frank et al. 1997b; Frank
et al. 1998a, 1998b, 1998c, 1998d; Kauppinen et al.
1997; Corrigall et al. 1998; also see Human Gene Mu-
tation Database), whereas a further 9 mutations have
been identified only in its homozygous variant (Meissner
et al. 1996; Kauppinen et al. 1997; Frank et al. 1998e;
Roberts et al. 1998). Of the mutations in our patients,
31 (7 nonsense and 24 frameshift) introduce premature
stop codons (table 3) and are likely to abolish PPOX
activity, primarily by accelerating mRNA decay (Cul-
bertson 1999). The 10 splice-site mutations that we iden-
tified (table 3) either change invariant bases at the donor
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Figure 2 Missense mutations and intraexonic SNPs in human
PPOX. The amino acid sequence for the human enzyme (1) was com-
pared with those of the mouse (2), Saccharomyces cerevisiae (3), My-
xococcus xanthus (4), Bacillus subtilis (5)Mycobacterium tuberculosis
(6), Propionibacterium freundenreichii (7),Nicotiana tabacum I (plas-
tid) (8), Nicotiana tabacum II (mitochondria) (9), and Arabadopsis
thaliana (10). Comparisons are shown only for mutated residues; num-
bers refer to the human sequence; letters above numbers denotemutant
residues. Intraexonic polymorphisms (P256R [256] andR304H [304])
are in italics. A pair of vertically stacked asterisks ( ) denotes a∗∗
conserved residue, and a single asterisk (*) denotes a highly conserved
residue. Sequences were aligned by Clustal W1.7 (Thompson et al.
1994).
or acceptor site (Cooper and Krawczak 1993) or intro-
duce an alternative splice site that produces a frameshift
in mRNA for PPOX (table 3) and are also likely to
substantially reduce activity.
Twenty-five mutations altered the coding sequence for
PPOX (table 3). Three of these altered the translation-
initiation codon (table 3). Similar mutations in other
genes are known to decrease steady-state mRNA con-
centrations, through failure of initiation with premature
termination (Cooper and Krawczak 1993). The conse-
quences of the 22 other missense mutations that we have
identified are more difficult to predict, because little is
known about the structure/function of PPOX. The hu-
man PPOX gene encodes a 51-kD protein that functions
as a flavin- and oxygen-dependent protoporphyrino-
gen oxidase associated with the inner mitochondrial
membrane (Deybach et al. 1985; Nishimura et al. 1995;
Dailey and Dailey 1996). Sequence analysis shows both
a dinucleotide-binding motif, in the amino-terminal re-
gion, that is highly conserved among flavin adenine di-
nucleotide (FAD)–binding proteins (Nishimura et al.
1995; Dailey and Dailey 1998) and an adjacent 60-res-
idue-long region that is similar throughout a superfamily
of FAD-binding proteins (Dailey and Dailey 1998).
There is no identifiable transmembrane domain (Dailey
and Dailey 1996), and the absence of a mitochondrial
targeting presequence suggests the presence of an inter-
nal targeting signal that remains to be identified. Other
than the initial methionine, 12 of the 20 residues that
are changed by missense mutations are highly conserved
between mammals, bacteria, and plants (fig. 2) and are
therefore likely to be essential for PPOX function, sta-
bility, or transport. One of these (L15F) lies in the FAD-
binding site, whereas two others (R38P and G40E) are
in the adjacent region shared by the FAD-binding protein
superfamily (Dailey and Dailey 1998). Seven (35%) of
the residues are substituted by proline, with five of them
being leucine-to-proline mutations, and a similar mu-
tation (S450P) has been reported elsewhere (Frank et al.
1998d). The high frequency of mutations of proline is
unusual and, since this residue is known to decrease
protein flexibility (Tian et al. 1998) and to interrupt a-
helical regions, may suggest that PPOX is very sensitive
to small structural changes. Two other missense muta-
tions (V282D and 281delH) introduce major changes
(charge alteration or deletion) at adjacent residues that
are partially conserved (fig. 2).
We have recently shown that missense PPOX muta-
tions that preserve 10%–25% of wild-type activity are
present on at least one allele in all patients with the rare
homozygous form of VP (Roberts et al. 1998). None of
these were found in our study, and it has yet to be shown
that such mild mutations ever cause clinically overt VP
in heterozygotes. It seems likely that such mutations rep-
resent one end of a functional spectrum of PPOX mis-
sense mutations, with mutations that abolish activ-
ity—and that therefore are lethal in homozygotes and
thus only found in VP—at the other end. The frameshift,
stop, and at least some of the missense mutations that
we have identified are likely to abolish activity. It seems
probable that mutations with intermediate effect on cat-
alytic activity also exist and may cause VP, but with a
low clinical penetrance. Further studies may show that
some of the missense and splice-defective mutations in
our patients fall into this category.
VP shows less allelic heterogeneity in western Europe
than is shown by other acute hepatic porphyrias. In
France and the United Kingdom, all the mutations iden-
tified in theHBMS (hydroxymethylbilane synthase) gene
in 166 unrelated patients with acute intermittent por-
phyria have a prevalence of !5%—apart from one mu-
tation (R173W) in the United Kingdom, which has a
prevalence of 10% (Puy et al. 1997; Whatley et al.
1999). Hereditary coproporphyria is similarly hetero-
geneous in both France and the United Kingdom (Ro-
sipal et al. 1999; authors’ unpublished data). In contrast,
five of the mutations that we have identified in VP have
prevalences, in these two countries, of 7%–12%. Anal-
ysis of intragenic SNPs showed that at least two of these
mutations are likely to have arisen on more than one
occasion, so their relatively high frequency cannot be
explained solely by their presence in the population of
extended families. The apparent difference, in hetero-
geneity, between France and the United Kingdom (table
3) requires further investigation, but neither country
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shows the predominance of a single mutation seen in
South Africa and, to a lesser extent, Finland (Kauppinen
et al. 1997). In addition, even though the frequencies of
SNPs were similar, there was an almost complete sep-
aration between the types of mutation found in France
and those found in the United Kingdom, with only two
infrequent mutations (R168H and 745delG) being pre-
sent in both populations; both of these occur at hyper-
mutable sites, and one of them (R168H) has been found
in other countries (de Rooij et al. 1997; Frank et al.
1998b). This separation suggests a relatively recent or-
igin for the mutations in our families. The R59W South
African founder mutation was not present in any of our
patients. To date, it has been identified only in Afrikans
families of Dutch descent (Kirsch et al. 1998) and in the
Netherlands (De Rooij et al. 1997).
Previous reports of VP outside South Africa (Musta-
joki 1980; Arnas et al. 1992; Kirsch et al. 1998) have
included too few symptomatic patients for any firm con-
clusions to be drawn about whether the clinical features
reported from South Africa (Eales et al. 1980; Kirsch et
al. 1998) are special to that country or typical of the
disease in general. Here we have shown that the clinical
features in a large, molecularly heterogeneous series
from western Europe are identical to those seen in South
Africa, where almost all patients share the same muta-
tion (Meissner et al. 1996; Groenewald et al. 1998). This
finding suggests that VP in South Africa is clinically rep-
resentative of the disease elsewhere and that allelic het-
erogeneity does not substantially alter the clinical pat-
tern—an observation that would be predicted if the
majority of PPOXmutations that cause VP lead to near-
complete or total loss of activity, as does the R59W
mutation in South Africa (Meissner et al. 1996). Mea-
surements of PPOX activity in South African and other
patients with VP have consistently shown a 50% de-
crease, consistent with complete haplodeficiency (Bren-
ner and Bloomer 1980; Da Silva et al. 1995; Kirsch et
al. 1998). More detailed analysis of our findings also
fails to identify any major relationship between clinical
features and type of mutation. Of the mutations that we
identified, 31 (47%) produced premature-termination
codons and are likely to have abolished all PPOX ac-
tivity. Yet the distribution of the associated clinical fea-
tures was similar to that found in the group as a whole
(tables 4 and 5), and there was no significant correlation
between type of mutation and clinical presentation (table
5). In addition, four of the five relatively frequent mu-
tations that we found were associated with two or more
clinical presentations. Overall, therefore, the genotype
does not appear to be a significant determinant of clinical
severity, if skin disease alone is regarded as a mild man-
ifestation and if an acute attack is regarded as a severe
one. Environmental influences and genetic effects from
other loci are likely to be more important in this respect.
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